Chargement en cours...
Development and targeted use of nilotinib in chronic myeloid leukemia
The development of imatinib has resulted in sustained hematologic and cytogenetic remissions in all phases of chronic myeloid leukemia (CML). Despite the high efficacy, relapses have been observed and are much more prevalent in patients with advanced disease. The most common mechanism of acquired re...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove Medical Press
2009
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2761189/ https://ncbi.nlm.nih.gov/pubmed/19920910 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|